-+ 0.00%
-+ 0.00%
-+ 0.00%

GH Research's $1.2B Depression Drug Opportunity Still Has Analysts Buying the Dip

Benzinga·11/16/2026 16:38:38
Listen to the news

Shares of GH Research PLC (NASDAQ:GHRS) fell in early trading on Monday after the company announced initial FDA feedback on the proposed Phase 3 pivotal TRD program design.

Here are some key analyst takeaways:

Check out other analyst stock ratings.

Needham: GH Research’s stock climbed following the third-quarter results, during which the company announced positive early-stage (Phase 2a) results for its drug GH001 in postpartum depression (PPD), Fadia said in a note. Based on these results, the company plans to launch a late-stage (pivotal) PPD trial in the second half of 2027, she added.

The final FDA design meeting for a separate Phase 3 program in treatment-resistant depression (TRD) has been pushed to the first quarter of 2027, the analyst noted. Additionally, GH Research confirmed that its upgraded aerosol inhaler delivers more consistent dosing than older devices, allowing patients to receive a single dose during a quick one-hour clinic visit instead of up to three separate doses, she added.

TD Cowen: GH Research announced positive initial FDA feedback regarding the design of its upcoming late-stage (Phase 3) clinical trials for TRD, Baral said. The final design meeting is set with the FDA for early 2027 to confirm dosing and retreatment rules before launching two pivotal TRD trials, she added.

GH Research reported a net loss of 18 cents per share and exited the quarter with $350.6 million in cash, which gives the company enough funding to operate well into 2027, the analyst stated.

"Pending positive clinical data, we see the potential for approximately ~$1.2BN in peak sales given the substantial unmet need in TRD," she further wrote.

GHRS Price Action: Shares of GH Research had declined by 2.36% to $18.65 at the time of publication on Monday.